Study of N-homocysteinylation of Key Proteins in Alzheimer's Disease (HO-MA)

Alzheimer Disease Clinical Trial

— HO-MA  

Official title:

Study of N-homocysteinylation of Key Proteins in Alzheimer's Disease

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06168955
• Other study ID #: 2023-A01502-43
• Status: Not yet recruiting
• Phase: N/A
• Start date: February 2024
• Est. completion date: December 2025

Study information

• Verified date: January 2024
• Source: Central Hospital, Nancy, France
• Contact: Mathilde Renaud
• Phone: 0380425485
• Email: cppest1[@]chlcdijon.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Alzheimer's disease (AD) is the leading cause of dementia in France. It is a multifactorial pathology, combining genetic and environmental risk factors. Homocysteine, a sulfur-containing amino acid belonging to the methionine-monocarbon cycle, has frequently been found at high levels in neurodegenerative diseases, and in AD in particular. It has been shown on human brain sections that the interaction of homocysteine with tau and MAP1, two key AD proteins, was significantly higher in AD patients than in controls, and corresponded to an N-homocysteinylation type interaction.

This is a prospective study, the main objective of which is to compare MAP1 N-homocysteinylation levels in fibroblasts from individuals with AD versus disease-free cell lines.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: December 2025
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• age > 18 years

• Age of onset of AD < 75 years

• Person with AD with positive CSF biomarkers

• Person who has previously benefited from an analysis of AD genetic characteristics (APP, PSEN1, PSEN2, TREM2, ABCA7, SORL1 genes and ApoE status) and an analysis of monocarbon metabolism genes in the case of biochemical abnormalities by clinical exome, targeted panel or complete exome, and for whom the data set is already available.

Exclusion Criteria:

• Pregnant, parturient or breast-feeding women

• Minor (not emancipated)

• Person of legal age (subject to a legal protection measure)

• Adult unable to give consent

Related Conditions & MeSH terms

• Alzheimer Disease

Intervention

Other:
• skin biopsy
skin biopsy for cell culture and N-homocysteinylation study

Locations

Country	Name	City	State
France	Centre Hospitalier Régional Universitaire de Nancy	Nancy

Sponsors (1)

Lead Sponsor	Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MAP1 homocysteinylation level		Baseline
Secondary	Homocysteinylation level of tau protein		baseline